IL13RA2 and adrenal cortex carcinoma: In the Phase 1 trial of IL-13-PE, three out of six IL-13Rα2-positive ACC patients developed disease stability lasting for 2 to 5.5 months, suggesting that IL-13Rα2-targeting immunotherapy may have antitumor efficacy and could be a novel treatment for ACC in the future (71).